HomeCompareDRRX vs KMB

DRRX vs KMB: Dividend Comparison 2026

DRRX yields 104.71% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DRRX wins by $4.67M in total portfolio value
10 years
DRRX
DRRX
● Live price
104.71%
Share price
$1.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.71M
Annual income
$1,637,812.78
Full DRRX calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — DRRX vs KMB

📍 DRRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDRRXKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DRRX + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DRRX pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DRRX
Annual income on $10K today (after 15% tax)
$8,900.52/yr
After 10yr DRIP, annual income (after tax)
$1,392,140.86/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, DRRX beats the other by $1,387,701.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DRRX + KMB for your $10,000?

DRRX: 50%KMB: 50%
100% KMB50/50100% DRRX
Portfolio after 10yr
$2.38M
Annual income
$821,517.56/yr
Blended yield
34.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on DRRX right now

DRRX
Analyst Ratings
8
Buy
5
Hold
Consensus: Buy
Altman Z
-67.3
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DRRX buys
0
KMB buys
0
No recent congressional trades found for DRRX or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDRRXKMB
Forward yield104.71%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$4.71M$45.9K
Annual income after 10y$1,637,812.78$5,222.34
Total dividends collected$4.23M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: DRRX vs KMB ($10,000, DRIP)

YearDRRX PortfolioDRRX Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$21,171$10,471.20$11,314$614.45+$9.9KDRRX
2$43,372$20,718.50$12,867$760.19+$30.5KDRRX
3$86,075$39,667.56$14,713$945.27+$71.4KDRRX
4$165,674$73,573.88$16,924$1,181.90+$148.8KDRRX
5$309,620$132,347.88$19,596$1,486.64+$290.0KDRRX
6$562,449$231,156.47$22,850$1,882.16+$539.6KDRRX
7$994,265$392,443.71$26,849$2,399.80+$967.4KDRRX
8$1,712,217$648,353.89$31,812$3,083.36+$1.68MDRRX
9$2,875,555$1,043,482.55$38,033$3,994.72+$2.84MDRRX
10$4,714,656$1,637,812.78$45,918$5,222.34+$4.67MDRRX

DRRX vs KMB: Complete Analysis 2026

DRRXStock

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Full DRRX Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this DRRX vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DRRX vs SCHDDRRX vs JEPIDRRX vs ODRRX vs KODRRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.